Last reviewed · How we verify
TAK-925
At a glance
| Generic name | TAK-925 |
|---|---|
| Sponsor | Takeda |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery (PHASE2)
- A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia (PHASE1)
- A Study of Danavorexton (TAK-925) in Adults With Obstructive Sleep Apnea (PHASE1)
- A Study of Danavorexton in Anesthetized Adults (PHASE1)
- Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Participants With Narcolepsy (PHASE1)
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-925 Study in Sleep-Deprived Healthy Adults (PHASE1)
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Participants With Narcolepsy (PHASE1)
- Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAK-925 CI brief — competitive landscape report
- TAK-925 updates RSS · CI watch RSS
- Takeda portfolio CI